IP CISPLATIN IN PATIENTS WITH MALIGNANT ASCITES - PHARMACOKINETIC EVALUATION AND COMPARISON WITH THE IV ROUTE

  • 1 January 1983
    • journal article
    • research article
    • Vol. 67  (3) , 235-238
Abstract
I.p. chemotherapy may be useful in managing patients with malignant ascites. This approach should result in a high concentration of drug at the site of disease, while the plasma concentration and therefore systemic toxicity remain low. Six patients with malignant ascites [2 with adenocarcinoma of the breast, 4 with ovarian cancer] were treated with cisplatin at a dose of 60 mg/m2. Three patients received the drug i.v.; one one of these patients and 3 other patients were treated with i.p. cisplatin. Pt concentrations in plasma, ascites, protein-free ultrafiltrates of plasma and ascites, and urine were assayed by flameless atomic absorption spectrophotometry. The area under the concentration .times. time curve for ultrafilterable Pt in ascites was 30 times greater after i.p. administration of cisplatin than after i.v. cisplatin. I.p. cisplatin can be administered safely to patients with malignant ascites and may be useful in patients with minimal residual intraperitoneal disease, particularly ovarian carcinoma.